Neurogene Closes $115 Million Series B Financing
Neurogene Closes $115 Million Series B Financing Neurogene Closes $115 Million Series B Financing Neurogene Inc., a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115 million Series B financing. The financing round was led by EcoR1 Capital, with participation from existing investors Redmile Group, Samsara BioCapital, Cormorant Asset Management and an undisclosed leading healthcare investment fund. New investors include funds and accounts managed by BlackRock, funds managed by Janus ...